Search Results
201 results found-
Share buy-backs were undertaken at higher prices than the original subscription prices which reduced the historical balance for ordinary share contributed equity to nil.
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
GESP, including details of shares issued under the scheme, is set Due to share buy-backs being undertaken at higher prices than out in Note 5.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
Closing balance 195.1 168.2 29.1 126.0 224.2 294.2 Due to share buy-backs being undertaken at higher prices than the original subscription prices, the balance for ordinary share contributed equity has been reduced to nil, and a reserve created to reflect the excess value of Nature and purpose of reserves shares bought over the original amount of subscribed capital.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
Nature and purpose of reserves Due to share buy-backs being undertaken at higher prices i. Share-based payments reserve than the original subscription prices, the balance for ordinary The share-based payments reserve is used to recognise the share contributed equity has been reduced to nil, and a reserve fair value of options, performance rights and GESP rights created to reflect the excess value of shares bought over the issued to employees.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2017-full.pdf -
and GESP, including details of shares issued under the scheme, Due to share buy-backs being undertaken at higher prices is set out in Note 5.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
i. Share-based payments reserve Due to share buy-backs being undertaken at higher prices than The share-based payments reserve is used to recognise the the original subscription prices, the balance for ordinary share fair value of options, performance rights and GESP rights contributed equity has been reduced to nil, and a reserve created issued to employees.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2016-full.pdf -
Biotech leader CSL has manufacturing centers, sales offices, and locations to serve patients and public health around the globe.
https://www.csl.com/we-are-csl/worldwide-locations -
The agreement was announced last month and under the terms of the agreement, Arcturus Therapeutics will receive an upfront payment of US$200 million and will be eligible to receive further payments dependent upon the achievement of certain development and commercial milestones along with royalties/profit sharing on future product sales. "
https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics